PANTHERx® Rare Pharmacy Selected by Blueprint Medicines to Distribute GAVRETO™ (pralsetinib) for the Treatment of Adults with Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Blueprint Medicines...
Read More
PANTHERx® Rare Pharmacy Selected by Ultragenyx Pharmaceutical to Distribute DOJOLVI™ (triheptanoin), for Patients with Long-Chain Fatty Acid Oxidation Disorders (LC-FAOD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Ultragenyx Pharmaceutical...
Read More
PANTHERx® Chosen as Exclusive Rare Pharmacy Partner by Viela Bio, Inc. for Uplizna™ (inebilizumab-cdon) for Adult Patients with AQP4+ Neuromyelitis Optica Spectrum Disorder (NMOSD)
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Viela Bio, Inc....
Read More
PANTHERx Rare Pharmacy Recognized as a US Best Managed Company
Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy (PANTHERx), was officially recognized as a prestigious US...
Read More
PANTHERx® Rare Pharmacy Selected by Deciphera Pharmaceuticals to Distribute QINLOCK™ (ripretinib), for Gastrointestinal Stromal Tumor (GIST) Patients
Read the Official PANTHERx Press Release. PANTHERx® Rare Pharmacy announces that it has been selected by Deciphera Pharmaceuticals...
Read More
PANTHERx Rare Pharmacy Wins Patient Choice Award for a Record Third Time
Read the Official PANTHERx Press Release. PANTHERx Rare Pharmacy (PANTHERx) has again been recognized as the winner of the...
Read More
